Life Biosciences advanced its clinical epigenetic reprogramming program after raising a fully subscribed $80 million Series D. The funding supports ER-100, which is in phase I trials testing the approach of reversing biological effects of aging via partial epigenetic reprogramming. The company said the round will fund operations into the second half of 2027 and support ER-100’s progression through early clinical milestones. The company previously raised an $82 million Series C in January 2022 and smaller earlier rounds in 2019. For the field, the financing adds weight to clinical investment in epigenetic reset strategies and reinforces investor appetite for modalities that target aging-related biology through controlled, partial pathway modulation.